Notice: Global Information Announces Listing on JASDAQ Standard Market of the Tokyo Stock Exchange

Cover Image
Market Research Report

Europe Advanced Wound Care Market - Industry Trends and Forecast to 2027

Published by Data Bridge Market Research Private Limited Product code 570380
Published Content info 206 Pages
Delivery time: 1-2 business days
Price
Back to Top
Europe Advanced Wound Care Market - Industry Trends and Forecast to 2027
Published: August 1, 2020 Content info: 206 Pages
Description

Europe advanced wound care market is projected to register a CAGR of 4.8% in the forecast period of 2020 to 2027. The new market report contains data for historic year 2018, the base year of calculation is 2019 and the forecast period is 2020 to 2027.

Market Segmentation

Europe Advanced Wound Care Market, By Product Type (Dressing, Therapy Devices, Biologics and Others), Wound Type (Primary Wound Care, Secondary Wound Care and Tertiary Wound Care), End User (Hospitals, Wound Care Centers, Ambulatory Centers, Home Healthcare, Clinics and Others), Distribution Channel (Direct Tenders and Retail), Country (U.K., Italy, France, Germany, Spain, Belgium, Turkey, Netherlands, Switzerland and Rest of Europe) Industry Trends and Forecast to 2027

Market Players

The key market players of Europe advanced wound care market are listed below:

Smith and Nephew

3M

Medline Industries, Inc.

Molnlycke Health Care AB

ConvaTec Group PLC

Coloplast Group

B. Braun Melsungen AG

LifeSciences Corporation

Johnson & Johnson Services, Inc.

PAUL HARTMANN LIMITED

Hollister Incorporated

Zimmer Biomet

AVERY DENNISON CORPORATION

MEDTRONIC

ADVANCED MEDICAL SOLUTIONS GROUP PLC

Cardinal Health

Baxter

Advancis Medical UK

Table of Contents

TABLE OF CONTENTS

1 INTRODUCTION 25

  • 1.1 OBJECTIVES OF THE STUDY 25
  • 1.2 MARKET DEFINITION 25
  • 1.3 OVERVIEW OF EUROPE ADVANCED WOUND CARE MARKET 26
  • 1.4 CURRENCY AND PRICING 27
  • 1.5 LIMITATIONS 27
  • 1.6 MARKETS COVERED 27

2 MARKET SEGMENTATION 31

  • 2.1 MARKETS COVERED 31
  • 2.2 GEOGRAPHICAL SCOPE 32
  • 2.3 YEARS CONSIDERED FOR THE STUDY 32
  • 2.4 CURRENCY AND PRICING 32
  • 2.5 DBMR TRIPOD DATA VALIDATION MODEL 33
  • 2.6 MULTIVARIATE MODELLING 36
  • 2.7 PRODUCT TYPE LIFELINE CURVE 36
  • 2.8 VENDOR SHARE ANALYSIS 37
  • 2.9 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 38
  • 2.10 DBMR MARKET POSITION GRID 39
  • 2.11 SECONDARY SOURCES 41
  • 2.12 ASSUMPTIONS 41

3 EXECUTIVE SUMMARY 42

4 PREMIUM INSIGHTS 45

5 IMPACT OF COVID-19 ON EUROPE ADVANCED WOUND CARE MARKET 46

  • 5.1 IMPACT ANALYSIS ON DEMAND 46
  • 5.2 PRICE IMPACT 47
  • 5.3 CONCLUSION 47

6 MARKET OVERVIEW 48

  • 6.1 DRIVERS 50
    • 6.1.1 INCREASING CASES OF CHRONIC WOUNDS 50
    • 6.1.2 NEW PRODUCT LAUNCHES 51
    • 6.1.3 INCREASING NUMBER OF PATIENTS UNDERGOING SURGICAL PROCEDURES 52
    • 6.1.4 GROWING GERIATRIC POPULATION 52
    • 6.1.5 RISING AWARENESS PROGRAMS 54
    • 6.1.6 INCREASING RESEARCH AND DEVELOPMENT 54
  • 6.2 RESTRAINTS 56
    • 6.2.1 HIGH COST ASSOCIATED WITH THE TREATMENT 56
    • 6.2.2 STRINGENT MANUFACTURING POLICIES 56
    • 6.2.3 PRODUCT RECALL 57
  • 6.3 OPPORTUNITIES 57
    • 6.3.1 TECHNOLOGICAL ADVANCEMENT IN WOUND CARE 57
    • 6.3.2 STRATEGIC INITIATIVES BY THE COMPANIES 58
    • 6.3.3 INCREASING HEALTHCARE EXPENDITURE 59
  • 6.4 CHALLENGES 60
    • 6.4.1 LACK OF SKILLED LABOR FORCE 60
    • 6.4.2 INCREASE IN THE COMPETITION 60
    • 6.4.3 SIDE EFFECTS AND ADVERSE EFFECTS ASSOCIATED WITH CHRONIC WOUNDS 61

7 EUROPE ADVANCED WOUND CARE MARKET, BY PRODUCT TYPE 62

  • 7.1 OVERVIEW 63
  • 7.2 DRESSING 64
    • 7.2.1 FOAM DRESSING 65
    • 7.2.2 FILM DRESSING 65
      • 7.2.2.1 TRANSPARENT 65
      • 7.2.2.2 NON TRANSPARENT 66
    • 7.2.3 ALGINATE DRESSING 66
    • 7.2.4 HYDROCOLLOID DRESSING 66
    • 7.2.5 HYDROGEL DRESSING 66
    • 7.2.6 COLLAGEN DRESSING 66
    • 7.2.7 POLYACRYLATE DRESSING 66
    • 7.2.8 SUPER ABSORBENT DRESSING 66
      • 7.2.8.1 NON-ADHERENT 66
      • 7.2.8.2 ADHERENT 67
    • 7.2.9 WOUND CONTACT LAYER 67
    • 7.2.10 WOUND CLEANSERS 67
    • 7.2.11 HONEY DRESSING 67
    • 7.2.12 OTHERS 67
  • 7.3 THERAPY DEVICES 67
    • 7.3.1 NEGATIVE PRESSURE WOUND THERAPY (NPWT) 68
      • 7.3.1.1 DISPOSABLE NPWT DEVICES 68
      • 7.3.1.2 PORTABLE NPWT DEVICES 68
      • 7.3.1.3 STANDALONE NPWT DEVICES 69
    • 7.3.2 PHYSICAL THERAPIES 69
      • 7.3.2.1 LASER THERAPY 69
      • 7.3.2.2 EXTERNAL SHOCK WAVE THERAPIES 69
      • 7.3.2.3 ELECTRICAL STIMULATION 69
      • 7.3.2.4 OTHERS 69
    • 7.3.3 PRESSURE RELIEF DEVICES 70
      • 7.3.3.1 MATTRESS 70
      • 7.3.3.2 BED 70
    • 7.3.4 HYPERBARIC OXYGEN CHAMBERS 70
      • 7.3.4.1 MONOPLACE 70
      • 7.3.4.2 MULTIPLACE 71
      • 7.3.4.3 TOPICAL 71
    • 7.3.5 WOUND DEBRIDEMENT DEVICES 71
      • 7.3.5.1 ULTRASOUND 71
      • 7.3.5.2 HYDROSURGICAL 71
      • 7.3.5.3 MECHANICAL 71
      • 7.3.5.4 OTHERS 71
    • 7.3.6 OTHERS 72
  • 7.4 BIOLOGICS 72
    • 7.4.1 ALLOGRAFTS 73
      • 7.4.1.1 CULTURED ALLOGRAFTS 73
      • 7.4.1.2 HUMAN DERMAL LAYER 73
    • 7.4.2 XENOGRAFTS 73
    • 7.4.3 SYNTHETIC SKIN GRAFTS 73
    • 7.4.4 GROWTH FACTORS 73
      • 7.4.4.1 PLATELET DERIVED GROWTH FACTOR (PDGF) 74
      • 7.4.4.2 EPIDERMAL GROWTH FACTORS (EGF) 74
      • 7.4.4.3 GRANULOCYTE COLONY STIMULATING FACTORS (G-CSF) 74
      • 7.4.4.4 BASIC FIBROBLAST GROWTH FACTORS (BFGF) 74
      • 7.4.4.5 KERATINOCYTE GROWTH FACTORS (KGF) 74
      • 7.4.4.6 PLATELET RICH PLASMA (PRP) 74
      • 7.4.4.7 TALACTOFERRIN ALFA 75
      • 7.4.4.8 THROMBIN PEPTIDE (TP508) 75
      • 7.4.4.9 OTHERS 75
  • 7.5 OTHERS 75

8 EUROPE ADVANCED WOUND CARE MARKET, BY WOUND TYPE 76

  • 8.1 OVERVIEW 77
  • 8.2 PRIMARY WOUND CARE 78
    • 8.2.1 SURGICAL WOUNDS 78
      • 8.2.1.1 CLASS III 79
      • 8.2.1.2 CLASS IV 79
      • 8.2.1.3 CLASS II 79
      • 8.2.1.4 CLASS I 79
    • 8.2.2 ULCERS 79
      • 8.2.2.1 DIABETIC FOOT ULCERS 80
      • 8.2.2.2 VENOUS ULCERS 80
      • 8.2.2.3 PRESSURE ULCERS 80
      • 8.2.2.4 ARTERIAL LEG ULCERS 80
      • 8.2.2.5 OTHERS 80
  • 8.3 SECONDARY WOUND CARE 80
    • 8.3.1 TRAUMATIC WOUNDS 81
    • 8.3.2 BURNS 81
      • 8.3.2.1 THERMAL BURN 81
      • 8.3.2.2 ELECTRICAL BURN 81
      • 8.3.2.3 CHEMICAL BURN 81
      • 8.3.2.4 RADIATION BURN 81
      • 8.3.2.5 FRICTION BURN 82
    • 8.3.3 OTHERS 82
  • 8.4 TERTIARY WOUND CARE 82

9 EUROPE ADVANCED WOUND CARE MARKET, BY END USER 83

  • 9.1 OVERVIEW 84
  • 9.2 HOSPITALS 85
  • 9.3 WOUND CARE CENTERS 85
  • 9.4 AMBULATORY CENTERS 86
  • 9.5 HOME HEALTHCARE 86
  • 9.6 CLINICS 86
  • 9.7 OTHERS 86

10 EUROPE ADVANCED WOUND CARE MARKET, BY DISTRIBUTION CHANNEL 87

  • 10.1 OVERVIEW 88
  • 10.2 DIRECT TENDERS 90
  • 10.3 RETAIL 90

11 EUROPE ADVANCED WOUND CARE MARKET BY COUNTRY 91

  • 11.1 EUROPE 91
    • 11.1.1 GERMANY 102
    • 11.1.2 FRANCE 108
    • 11.1.3 U.K. 115
    • 11.1.4 ITALY 123
    • 11.1.5 SPAIN 130
    • 11.1.6 RUSSIA 137
    • 11.1.7 NETHERLANDS 144
    • 11.1.8 SWITZERLAND 151

12 EUROPE ADVANCED WOUND CARE MARKET, COMPANY LANDSCAPE 158

  • 12.1 COMPANY SHARE ANALYSIS: EUROPE 158

13 SWOT ANALYSIS 159

14 COMPANY PROFILE 160

  • 14.1 MEDLINE INDUSTRIES, INC. 160
    • 14.1.1 COMPANY SNAPSHOT 160
    • 14.1.2 PRODUCT PORTFOLIO 161
    • 14.1.3 RECENT DEVELOPMENT 168
  • 14.2 SMITH & NEPHEW 169
    • 14.2.1 COMPANY SNAPSHOT 169
    • 14.2.2 REVENUE ANALYSIS 169
    • 14.2.3 PRODUCT PORTFOLIO 170
    • 14.2.4 RECENT DEVELOPMENTS 171
  • 14.3 3M 172
    • 14.3.1 COMPANY SNAPSHOT 172
    • 14.3.2 REVENUE ANALYSIS 172
    • 14.3.3 PRODUCT PORTFOLIO 173
    • 14.3.4 RECENT DEVELOPMENT 173
  • 14.4 MOLNLYCKE HEALTH CARE AB 174
    • 14.4.1 COMPANY SNAPSHOT 174
    • 14.4.2 PRODUCT PORTFOLIO 174
    • 14.4.3 RECENT DEVELOPMENTS 175
  • 14.5 CONVATEC GROUP PLC 176
    • 14.5.1 COMPANY SNAPSHOT 176
    • 14.5.2 REVENUE ANALYSIS 176
    • 14.5.3 PRODUCT PORTFOLIO 177
    • 14.5.4 RECENT DEVELOPMENTS 177
  • 14.6 ADVANCED MEDICAL SOLUTIONS GROUP PLC 178
    • 14.6.1 COMPANY SNAPSHOT 178
    • 14.6.2 REVENUE ANALYSIS 178
    • 14.6.3 PRODUCT PORTFOLIO 179
    • 14.6.4 RECENT DEVELOPMENT 179
  • 14.7 ADVANCIS MEDICAL UK 180
    • 14.7.1 COMPANY SNAPSHOT 180
    • 14.7.2 PRODUCT PORTFOLIO 180
    • 14.7.3 RECENT DEVELOPMENT 181
  • 14.8 AVERY DENNISON CORPORATION 182
    • 14.8.1 COMPANY SNAPSHOT 182
    • 14.8.2 REVENUE ANALYSIS 182
    • 14.8.3 PRODUCT PORTFOLIO 183
    • 14.8.4 RECENT DEVELOPMENTS 183
  • 14.9 BAXTER 184
    • 14.9.1 COMPANY SNAPSHOT 184
    • 14.9.2 REVENUE ANALYSIS 184
    • 14.9.3 PRODUCT PORTFOLIO 185
    • 14.9.4 RECENT DEVELOPMENT 185
  • 14.10 B. BRAUN MELSUNGEN AG 186
    • 14.10.1 COMPANY SNAPSHOT 186
    • 14.10.2 REVENUE ANALYSIS 186
    • 14.10.3 PRODUCT PORTFOLIO 187
    • 14.10.4 RECENT DEVELOPMENTS 187
  • 14.11 CARDINAL HEALTH 188
    • 14.11.1 COMPANY SNAPSHOT 188
    • 14.11.2 REVENUE ANALYSIS 188
    • 14.11.3 PRODUCT PORTFOLIO 189
    • 14.11.4 RECENT DEVELOPMENTS 190
  • 14.12 COLOPLAST GROUP 191
    • 14.12.1 COMPANY SNAPSHOT 191
    • 14.12.2 REVENUE ANALYSIS 191
    • 14.12.3 PRODUCT PORTFOLIO 192
    • 14.12.4 RECENT DEVELOPMENTS 192
  • 14.13 HOLLISTER INCORPORATED 193
    • 14.13.1 COMPANY SNAPSHOT 193
    • 14.13.2 PRODUCT PORTFOLIO 193
    • 14.13.3 RECENT DEVELOPMENT 193
  • 14.14 INTEGRA LIFESCIENCES CORPORATION 194
    • 14.14.1 COMPANY SNAPSHOT 194
    • 14.14.2 REVENUE ANALYSIS 194
    • 14.14.3 PRODUCT PORTFOLIO 195
    • 14.14.4 RECENT DEVELOPMENTS 196
  • 14.15 JOHNSON & JOHNSON SERVICES, INC. 197
    • 14.15.1 COMPANY SNAPSHOT 197
    • 14.15.2 REVENUE ANALYSIS 197
    • 14.15.3 PRODUCT PORTFOLIO 198
    • 14.15.4 RECENT DEVELOPMENT 198
  • 14.16 MEDTRONIC 199
    • 14.16.1 COMPANY SNAPSHOT 199
    • 14.16.2 REVENUE ANALYSIS 199
    • 14.16.3 PRODUCT PORTFOLIO 200
    • 14.16.4 RECENT DEVELOPMENT 200
  • 14.17 PAUL HARTMANN LIMITED 201
    • 14.17.1 COMPANY SNAPSHOT 201
    • 14.17.2 PRODUCT PORTFOLIO 201
    • 14.17.3 RECENT DEVELOPMENT 201
  • 14.18 ZIMMER BIOMET 202
    • 14.18.1 COMPANY SNAPSHOT 202
    • 14.18.2 REVENUE ANALYSIS 202
    • 14.18.3 PRODUCT PORTFOLIO 203
    • 14.18.4 RECENT DEVELOPMENT 203

15 QUESTIONNAIRE 204

16 RELATED REPORTS 206

LIST OF FIGURES

  • FIGURE 1 EUROPE ADVANCED WOUND CARE MARKET : SEGMENTATION 28
  • FIGURE 2 EUROPE ADVANCED WOUND CARE MARKET : DATA TRIANGULATION 30
  • FIGURE 3 EUROPE ADVANCED WOUND CARE MARKET : DROC ANALYSIS 31
  • FIGURE 4 EUROPE ADVANCED WOUND CARE MARKET : COUNTRY VS REGIONAL MARKET ANALYSIS 32
  • FIGURE 5 EUROPE ADVANCED WOUND CARE MARKET : COMPANY RESEARCH ANALYSIS 32
  • FIGURE 6 EUROPE CANCER DIAGNOSTICS MARKET: VENDOR SHARE ANALYSIS 34
  • FIGURE 7 EUROPE ADVANCED WOUND CARE MARKET : INTERVIEW DEMOGRAPHICS 35
  • FIGURE 8 EUROPE ADVANCED WOUND CARE MARKET: DBMR MARKET POSITION GRID 36
  • FIGURE 9 EUROPE ADVANCED WOUND CARE MARKET : SEGMENTATION 41
  • FIGURE 10 INCREASING CASES OF CHRONIC WOUNDS AND NEW PRODUCT LAUNCHES ARE EXPECTED TO THE DRIVE THE EUROPE ADVANCED WOUND CARE MARKET IN THE FORECAST PERIOD OF 2020 TO 2027 42
  • FIGURE 11 DRESSING SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE ADVANCED WOUND CARE MARKET IN 2020 & 2027 42
  • FIGURE 12 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE EUROPE ADVANCED WOUND CARE MARKET 46
  • FIGURE 13 TOP TEN COUNTRIES/TERRITORIES FOR NUMBER OF NEW CASES OF TYPE 1 DIABETES (CHILDREN AND ADOLESCENTS <20 YEARS), PER YEAR 47
  • FIGURE 14 AGEING EUROPE POPULATION (IN MILLION) 50
  • FIGURE 15 HEALTHCARE EXPENDITURE IN FEW COUNTRIES (2015 & 2016) 56
  • FIGURE 16 EUROPE ADVANCED WOUND CARE MARKET:BY PRODUCT TYPE, 2019 60
  • FIGURE 17 EUROPE ADVANCED WOUND CARE MARKET: BY WOUND TYPE, 2019 74
  • FIGURE 18 EUROPE ADVANCED WOUND CARE MARKET: BY END USER, 2019 81
  • FIGURE 19 EUROPE ADVANCED WOUND CARE MARKET: BY DISTRIBUTION CHANNEL, 2019 85
  • FIGURE 20 EUROPE ADVANCED WOUND CARE MARKET: SNAPSHOT (2019) 87
  • FIGURE 21 EUROPE ADVANCED WOUND CARE MARKET: BY COUNTRY (2019) 88
  • FIGURE 22 EUROPE ADVANCED WOUND CARE MARKET: BY COUNTRY (2020 & 2027) 88
  • FIGURE 23 EUROPE ADVANCED WOUND CARE MARKET: BY COUNTRY (2020 & 2027) 89
  • FIGURE 24 EUROPE ADVANCED WOUND CARE MARKET: BY PRODUCT TYPE (2018-2027) 89
  • FIGURE 25 EUROPE ADVANCED WOUND CARE MARKET: COMPANY SHARE 2019 (%) 147
Back to Top